Alnylam Pharmaceuticals Ebitda Over Time
| ALNY Stock | USD 244.89 1.91 0.77% |
With this module, investors can use any or all of fundamental ratio historical patterns as a complementary method for asset selection as well as a tool for deciding entry and exit points. Many technical investors use fundamentals to limit their universe of possible portfolio assets.
Check out Alnylam Pharmaceuticals Performance and Alnylam Pharmaceuticals Correlation. Alnylam |
Is Biotechnology space expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Alnylam Pharmaceuticals. If investors know Alnylam will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Alnylam Pharmaceuticals listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Earnings Share (2.62) | Revenue Per Share 16.524 | Quarterly Revenue Growth (0.33) | Return On Assets (0.03) | Return On Equity (15.01) |
The market value of Alnylam Pharmaceuticals is measured differently than its book value, which is the value of Alnylam that is recorded on the company's balance sheet. Investors also form their own opinion of Alnylam Pharmaceuticals' value that differs from its market value or its book value, called intrinsic value, which is Alnylam Pharmaceuticals' true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Alnylam Pharmaceuticals' market value can be influenced by many factors that don't directly affect Alnylam Pharmaceuticals' underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between Alnylam Pharmaceuticals' value and its price as these two are different measures arrived at by different means. Investors typically determine if Alnylam Pharmaceuticals is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Alnylam Pharmaceuticals' price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.
Cross Equities Ebitda Analysis
Compare Alnylam Pharmaceuticals and related stocks such as ProQR Therapeutics, Wave Life Sciences, and Blueprint Medicines Corp Ebitda Over Time
Select Fundamental| 2010 | 2011 | 2012 | 2013 | 2014 | 2015 | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| PRQR | (3.2 M) | (3.2 M) | (3.2 M) | (3.2 M) | (16.6 M) | (29.8 M) | (40.2 M) | (40.9 M) | (41.1 M) | (57.3 M) | (136.6 M) | (54.9 M) | (56.5 M) | (24.1 M) | (25.3 M) |
| WVE | (3.3 M) | (3.3 M) | (3.3 M) | (3.3 M) | (4.9 M) | (18.7 M) | (55.6 M) | (102 M) | (157.3 M) | (213.2 M) | (143.4 M) | (117.2 M) | (152.6 M) | (58.8 M) | (61.7 M) |
| BPMC | (20.3 M) | (20.3 M) | (20.3 M) | (20.3 M) | (39.2 M) | (52.1 M) | (72 M) | (147.9 M) | (236.6 M) | (361.3 M) | 308.7 M | (628.3 M) | (515.4 M) | (474.6 M) | (450.9 M) |
| APLS | (4 M) | (4 M) | (4 M) | (4 M) | (11.3 M) | 6.4 M | (27.3 M) | (50.6 M) | (125.1 M) | (282.8 M) | (312.2 M) | (731.3 M) | (617.4 M) | (495.2 M) | (470.5 M) |
| INCY | (4.7 M) | (116.2 M) | 1.9 M | (14.8 M) | (1.5 M) | 57.7 M | 166.8 M | (218.5 M) | 187.2 M | 473.9 M | (178.2 M) | 630.2 M | 599.6 M | 919.4 M | 965.4 M |
| UTHR | (13.8 M) | 321.1 M | 484.5 M | 297 M | 542.8 M | 699.2 M | 1.1 B | 1 B | 826.3 M | (120.8 M) | 646.3 M | 736.8 M | 1 B | 1.4 B | 1.5 B |
| RARE | (6.5 M) | (6.5 M) | (16 M) | (34.6 M) | (56.1 M) | (146.4 M) | (244.6 M) | (323.1 M) | (541.7 M) | (411.7 M) | (139.8 M) | (410.3 M) | (640.5 M) | (516.5 M) | (490.6 M) |
| BMRN | (12.7 M) | (32 M) | (91.9 M) | (118.8 M) | (137.8 M) | (287.3 M) | (192.4 M) | (71.7 M) | (100.2 M) | (22.2 M) | (5.8 M) | 48 M | 267.5 M | 310.3 M | 325.8 M |
| EXEL | (15.3 M) | 101.1 M | (105.6 M) | (198.3 M) | (212.5 M) | (120 M) | (22.3 M) | 167.2 M | 452.1 M | 377.8 M | 119.2 M | 300.3 M | 222.4 M | 196.6 M | 206.4 M |
| HALO | (39.8 K) | (19.8 M) | (52.5 M) | (79.2 M) | (61.3 M) | (25.8 M) | (80.8 M) | 83.2 M | (66.9 M) | (63.5 M) | 147.5 M | 278.9 M | 315.5 M | 451.9 M | 474.5 M |
| KRYS | (1.1 M) | (1.1 M) | (1.1 M) | (1.1 M) | (1.1 M) | (1.1 M) | (1.1 M) | (4.7 M) | (11.8 M) | (21.3 M) | (30.3 M) | (65.3 M) | (145.2 M) | 17.9 M | 18.8 M |
| MDGL | (401 K) | (44 M) | (60.2 M) | (87 M) | (83.3 M) | (66.9 M) | (25.2 M) | (32 M) | (40.6 M) | (94.9 M) | (206.2 M) | (242.1 M) | (293.1 M) | (380 M) | (361 M) |
| DAWN | (14.9 M) | (14.9 M) | (14.9 M) | (14.9 M) | (14.9 M) | (14.9 M) | (14.9 M) | (14.9 M) | (14.9 M) | (14.9 M) | (43.7 M) | (72.5 M) | (146.4 M) | (206.1 M) | (195.8 M) |
Alnylam Pharmaceuticals and related stocks such as ProQR Therapeutics, Wave Life Sciences, and Blueprint Medicines Corp Ebitda description
My Equities
My Current Equities and Potential Positions
| Alnylam Pharmaceuticals | ALNY |
Specialization | Health Care, Pharmaceuticals, Biotechnology & Life Sciences |
| Location | Massachusetts; U.S.A |
| Exchange | NASDAQ Exchange |
USD 244.89
Additional Tools for Alnylam Stock Analysis
When running Alnylam Pharmaceuticals' price analysis, check to measure Alnylam Pharmaceuticals' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Alnylam Pharmaceuticals is operating at the current time. Most of Alnylam Pharmaceuticals' value examination focuses on studying past and present price action to predict the probability of Alnylam Pharmaceuticals' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Alnylam Pharmaceuticals' price. Additionally, you may evaluate how the addition of Alnylam Pharmaceuticals to your portfolios can decrease your overall portfolio volatility.